China Resources Double Crane: Subsidiary Ganlu Alcohol Injection Approved for New Specifications

LightningPacketLoss · 2026-04-08T07:17:35+00:00

China Resources Shuanghe's wholly-owned subsidiary Jingxi Shuanghe recently received approval from the National Medical Products Administration for an additional 3000ml:150g specification of Mannitol Injection, with an investment of 1.45 million yuan in R&D. It is expected that by 2025, the company's sales revenue will reach 71.13 million yuan, with global market sales amounting to $133 million.

LightningPacketLoss

2026-04-08 07:17:35

Abstract generation in progress

Recently, China Resources Shuanghe released an announcement stating that its wholly owned subsidiary, Jingxi Shuanghe, has recently received a 《Drug Supplementary Application Approval Notice》 for Mannitol Injection issued by the National Medical Products Administration. The content approved this time is the addition of the 3000ml:150g specification, with the aim of meeting the medication needs of different patient groups.

As of the date of the announcement, the company’s cumulative R&D investment for this drug was RMB 1.45 million. According to international market data, in 2024, the global sales revenue of Mannitol Injection was USD 133 million. In the domestic market, in 2025, the total sales revenue of Mannitol Injection was RMB 10.15M, of which Huarin Pharmaceutical, Chengdu Qingshan Likang Pharmaceutical, and Shijiazhuang Siya Pharmaceutical each accounted for market shares of 36.63%, 30.69%, and 27.36%, respectively. The company’s sales revenue of Mannitol Injection in 2025 was RMB 71.13 million.

(China Resources Shuanghe announcement)

(Editor: Yang Yan, Lin Chen)

Keywords:

                                                            Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.